猪口孝一

猪口 孝一（いのくち こういち、1955年6月13日 - ）は、日本の医師、教育者、日本医科大学名誉教授。専門は血液内科学、医学博士、日本医科大学大学院（1986年3月）。

社会福祉法人 仁生社 かつしか江戸川病院 院長。厚生労働省電離放射線業務上外検討委員。社会保険診療特別審査委員会審査委員。METイノベーションサミット実行委員会名誉会長。日本血液学会名誉会員。

 人物 
1955年、東京都葛飾区金町生まれ。1968年、葛飾区立末広小学校卒業後、金町中学校卒業。1971年、東京都立両国高等学校卒業後、山形大学医学部医学科に進学、1981年卒業。卒業後日本医科大学第3内科学教室に入局。1982年、日本医科大学大学院医学研究科入学（基礎系生化学第1専攻：宿谷良一教授指導）。1986年日本医科大学大学院医学研究科修了。1985年1月より米国国立公衆衛生院研究所（NIH）、Clinical Hematology Branchにvisiting fellowとして留学。帰国後、1989年日本医科大学医員助手、1992年日本医科大学講師、1999年日本医科大助教授、2004年日本医科大学内科学教授に任命される。2007年日本医科大学DNA実験安全委員長。2008年千葉北総病院血液内科部長兼消化器内科部長。2013年日本医科大学血液内科大学院教授、日本医科大学付属病院血液内科部長に任命される。2014年日本医科大学知的財産推進センター知財センター長。2021年日本医科大学大学院教授を定年退職。かつしか江戸川病院院長就任葛飾区医師会理事。

一男一女がいる。妻は衆議院議員 猪口幸子。弟は猪口正孝（東京都病院協会・会長、社会福祉法人正志会・会長）、親類に猪口雄二（全日本病院協会・会長、寿康会病院理事長）。

 受賞歴 
 1990年 日本医科大学同窓会医学研究助成金・受賞
 1991年 内藤記念科学奨励金・受賞
 1992年 上原記念生命科学財団研究奨励金・受賞
 1993年 日本医科大学医学会奨学賞・受賞 
 1996年 東京都医師会医学研究奨励賞・受賞
 2000年・2001年　高橋産業経済研究財団研究助成金・受賞

 原著 
 Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. Genes Chromosomes Cancer. 2018;57:401-408.
 Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res. 2018;66:66-72.
 Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.　　Leuk Res. 2018; 65:74-79.
 Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.　　Oncotarget. 2017 ; 8: 88904-88917.
 Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.　Cancer Sci. 2018 Jan;109:182-192. 
 The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase. Intern Med. 2018 Jan 1;57:17-23.
 Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. Ann Hematol. 2018 Jan;97:51-61.
 D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.　Ann Hematol. 2017 Oct;96:1641-1652. 
 Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. Genes Chromosomes Cancer. 2017 Nov;56:800-809.
 Amlexanox Downregulates S100A6 to Sensitize KMT2A/AFF1-Positive Acute Lymphoblastic Leukemia to TNFα Treatment.　Cancer Res. 2017 Aug 15;77:4426-4433
 Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Int J Clin Oncol. 2017 Oct;22:972-979. 
 D816V mutation in the KIT gene activation loop has a greater cell proliferative and anti-apoptotic ability than N822K mutation in core binding factor-acute myeloid leukemia. Ann Hematol. 2017 Oct;96:1641-1652. 
 Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report.Allergol Int. 2017 Jan 16. pii: S1323-893030177-0. doi: 10.1016/j.alit.2016.12.006. [Epub ahead of print] 
 A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma treatment. Leuk Res Rep.2016: 20;7: 2-5.
 Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncol Rep.2016: 36:2976-2982.
 The kinase-activating pathways and sensitivities to TKIs vary between fusion sites of RCSD1-ABL1 in Ph-like acute lymphoblastic leukemia. International Journal of Recent Scientific Research.2016 7: 9729-9733. 
 Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncol Rep.2016: 36:2976-2982.
 Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016 4:779-88.
 The Therapeutic Outcomes of Mechanical Ventilation in Hematological Malignancy Patients with Respiratory Failure. Intern Med. 2016 55:1537-45
 Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations. Haematologica. 2016 Sep;101:1074-81.
 Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. Biol Blood Marrow Transplant. 2016: 22:1125-32.
 Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma. 2016 57:2204-7.(Letter to the editor)
 Epstein-Barr Virus-positive T-cell Lymphoproliferative Disease Following Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia. J Nippon Med Sch.2016: 83; 35-42.
 Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, Kimura S, Tajika K, Gomi S, Arima N, Mori S, Ito S, Koizumi M, Ito Y, Wakita S, Arai K, Kitano T, Kosaka F, Dan K, Inokuchi K. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leukemia Research.2016: 40; 68-76.
 Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia. 30: 545-554.
 Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood 2015: 126; 2491-2501.
 Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. Int J Hematol.2015 102: 544-552.
 Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.Am J Hematol.2015;90:282-7. 
 Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. J Clin Exp Hematop.2014 54:197-204.
 Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol.2014. 99: 41-52.
 Establishment of MLL/AF4 transgenic mice with the phenotype of lymphoblastic leukemia or lymphoma. J Nippon Med Sch 2013: 80: 326-7.
 Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice. Bone Marrow Transplant. 2014:49:699-703.
 Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Br J Haematol 2013: 163: 286-289.
 Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 2013 104: 1146-53.
 Mutations of the epigenetics modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia.2013; 27: 1044-52.
 AAV-8 vector expressing IL-24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood.2012; 119: 64-71.
科学評論社　血液・腫瘍科　第59巻、6号　急性骨髄性白血病の分類とCD抗原、p:619-624, 2009年
文光堂　Medical Practice　27巻　臨時増刊号　治療薬の選択と使用法ガイドライン、骨髄腫 p: 302-306, 2010年　
科学評論社　血液内科　第73巻、3号　非定型慢性骨髄性白血病の臨床像とCSF3R, SETBP1異常の意義、p:345-348, 2016年
科学評論社　血液内科　第74巻、6号　Atg7抑制によるAML細胞の抗がん剤感受性増強、p:830-832, 2017年
日本経済新聞社　日系実力病院調査2018-2019版　p: 120
日本経済新聞社　日系実力病院調査2020-2021版　p: 116
日本医師会雑誌　第151巻・特別号 血液疾患のすべて　医療面接と病歴聴取 p:64-65, 2022年
科学評論社　血液内科　第84巻、1号　参照ガイドに基づく再生不良性貧血の治療　p:50-57. 2022年